https://reunionneuro.com/2022/08/11/field-trip-announces-closing-of-plan-of-arrangement-and-19-9-million-private-placement-financing/ 2023-07-18T21:27:47+00:00 monthly 0.2 https://reunionneuro.com/2022/08/15/reunion-neuroscience-inc-formerly-field-trip-health-ltd-reports-fiscal-first-quarter-2023-financial-results-completed-corporate-reorganization-on-august-11-2022/ 2023-07-18T21:05:50+00:00 monthly 0.2 https://reunionneuro.com/2022/08/16/reunion-neuroscience-inc-to-commence-trading-on-the-toronto-stock-exchange-on-august-17-2022/ 2023-07-18T20:41:53+00:00 monthly 0.2 https://reunionneuro.com/2022/08/29/field-trip-health-wellness-ltd-reports-fiscal-first-quarter-2023-financial-and-operating-results/ 2023-07-18T20:36:33+00:00 monthly 0.2 https://reunionneuro.com/2022/08/31/reunion-neuroscience-inc-announces-2022-annual-general-meeting-of-shareholders/ 2023-07-18T20:30:39+00:00 monthly 0.2 https://reunionneuro.com/2022/09/08/reunion-neuroscience-inc-to-participate-in-upcoming-investor-conferences/ 2023-07-18T20:25:27+00:00 monthly 0.2 https://reunionneuro.com/2022/09/28/reunion-neuroscience-inc-appoints-greg-mayes-as-president-and-chief-executive-officer/ 2023-07-18T20:18:13+00:00 monthly 0.2 https://reunionneuro.com/2022/09/29/reunion-neuroscience-inc-announces-results-of-annual-general-and-special-shareholder-meeting/ 2023-07-18T20:12:15+00:00 monthly 0.2 https://reunionneuro.com/2022/10/03/reunion-neuroscience-to-participate-in-the-cantor-neurology-psychiatry-conference/ 2023-07-18T19:42:34+00:00 monthly 0.2 https://reunionneuro.com/2022/10/07/reunion-neuroscience-inc-announces-executive-changes/ 2023-07-18T19:39:38+00:00 monthly 0.2 https://reunionneuro.com/2022/10/12/reunion-neuroscience-ceo-to-participate-on-panel-at-2022-horizons-perspectives-on-psychedelics-conference/ 2023-07-18T19:36:30+00:00 monthly 0.2 https://reunionneuro.com/2022/10/24/reunion-neuroscience-appoints-chief-financial-officer-and-vice-president-medical-affairs/ 2023-07-18T19:31:31+00:00 monthly 0.2 https://reunionneuro.com/2022/10/31/reunion-neuroscience-to-present-at-upcoming-november-conferences/ 2023-07-18T19:29:03+00:00 monthly 0.2 https://reunionneuro.com/2022/11/07/reunion-neuroscience-schedules-fiscal-second-quarter-2023-conference-call-for-monday-november-14-2022-at-830-a-m-et/ 2023-07-18T19:25:27+00:00 monthly 0.2 https://reunionneuro.com/2022/11/14/reunion-neuroscience-inc-provides-business-update-and-reports-fiscal-second-quarter-2023-financial-results/ 2023-07-18T18:56:31+00:00 monthly 0.2 https://reunionneuro.com/2022/11/18/reunion-neuroscience-puts-in-place-at-the-market-equity-facility/ 2023-07-18T18:47:40+00:00 monthly 0.2 https://reunionneuro.com/2022/12/06/reunion-neuroscience-inc-to-participate-in-upcoming-investor-conferences-in-december/ 2023-07-18T18:17:05+00:00 monthly 0.2 https://reunionneuro.com/2023/01/04/reunion-neuroscience-inc-provides-2023-corporate-update/ 2023-07-17T22:32:48+00:00 monthly 0.2 https://reunionneuro.com/2023/01/08/reunion-neuroscience-inc-completes-interim-data-analysis-for-phase-1-clinical-trial-with-novel-serotonergic-psychedelic-re104/ 2023-07-17T22:28:33+00:00 monthly 0.2 https://reunionneuro.com/2023/01/18/reunion-neuroscience-appoints-robert-alexander-as-chief-medical-officer/ 2023-07-17T22:20:58+00:00 monthly 0.2 https://reunionneuro.com/2023/02/02/reunion-neuroscience-schedules-fiscal-third-quarter-2023-conference-call-for-tuesday-february-14-2023-at-830-a-m-et/ 2023-07-17T22:15:34+00:00 monthly 0.2 https://reunionneuro.com/2023/02/14/reunion-neuroscience-provides-business-update-and-reports-fiscal-third-quarter-2023-financial-results/ 2023-07-17T22:09:47+00:00 monthly 0.2 https://reunionneuro.com/2023/03/07/reunion-neuroscience-to-participate-in-the-oppenheimer-annual-healthcare-conference/ 2023-07-17T21:51:40+00:00 monthly 0.2 https://reunionneuro.com/2023/03/13/reunion-neuroscience-files-lawsuit-against-mindset-pharma/ 2023-07-17T21:48:12+00:00 monthly 0.2 https://reunionneuro.com/2023/03/27/reunion-neuroscience-abstract-accepted-for-poster-presentation-at-2023-ascp-annual-meeting/ 2023-07-17T21:30:02+00:00 monthly 0.2 https://reunionneuro.com/2023/04/03/reunion-neuroscience-appoints-dr-fred-grossman-to-board-of-directors/ 2023-07-17T21:24:20+00:00 monthly 0.2 https://reunionneuro.com/2023/04/25/reunion-neuroscience-announces-presentation-at-2023-bloom-burton-co-healthcare-investor-conference/ 2023-07-17T21:06:25+00:00 monthly 0.2 https://reunionneuro.com/2023/04/25/reunion-neuroscience-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency/ 2023-07-17T21:14:28+00:00 monthly 0.2 https://reunionneuro.com/2023/06/01/reunion-neuroscience-announces-us13-1-million-take-private-transaction-with-mpm-bioimpact/ 2023-07-17T20:56:33+00:00 monthly 0.2 https://reunionneuro.com/2023/06/29/reunion-neuroscience-reports-fiscal-fourth-quarter-and-full-year-2023-financial-results-and-provides-a-corporate-update/ 2023-07-17T20:29:34+00:00 monthly 0.2 https://reunionneuro.com/2023/07/13/reunion-neuroscience-inc-shareholders-approve-proposed-plan-of-arrangement/ 2023-07-17T04:15:34+00:00 monthly 0.2 https://reunionneuro.com/2023/07/14/reunion-neuroscience-inc-obtains-final-court-order-for-proposed-plan-of-arrangement/ 2023-07-17T04:19:45+00:00 monthly 0.2 https://reunionneuro.com/2023/08/01/reunion-neuroscience-inc-and-mpm-bioimpact-announce-completion-of-plan-of-arrangement/ 2023-08-01T14:47:31+00:00 monthly 0.2 https://reunionneuro.com/2023/09/18/reunion-neuroscience-inc-announces-fda-clearance-of-ind-application-to-initiate-a-phase-2-study-of-re104-for-the-treatment-of-postpartum-depression/ 2024-05-02T13:37:51+00:00 monthly 0.2 https://reunionneuro.com/2023/10/05/reunion-neuroscience-inc-to-participate-in-october-investor-conferences/ 2024-05-02T13:37:22+00:00 monthly 0.2 https://reunionneuro.com/2024/04/03/reunion-neuroscience-inc-announces-upcoming-presentations-at-the-anxiety-and-depression-association-of-america-adaa-2024-conference/ 2024-05-02T13:36:51+00:00 monthly 0.2 https://reunionneuro.com/2024/04/15/fluence-and-reunion-neuroscience-inc-announce-partnership-on-phase-2-clinical-study-of-re104-for-postpartum-depression/ 2024-05-02T13:35:43+00:00 monthly 0.2 https://reunionneuro.com/2024/05/02/reunion-neuroscience-inc-announces-103-million-series-a-financing-co-led-by-mpm-bioimpact-and-novo-holdings/ 2024-05-02T13:32:34+00:00 monthly 0.2 https://reunionneuro.com/2024/05/20/reunion-neuroscience-announces-publication-of-results-from-early-preclinical-studies-demonstrating-the-potential-of-re104-for-development-in-depressive-disorders/ 2024-05-23T15:22:46+00:00 monthly 0.2 https://reunionneuro.com/2024/07/23/reunion-neuroscience-inc-announces-first-patient-dosed-in-phase-2-clinical-trial-of-re104-for-the-treatment-of-postpartum-depression/ 2024-07-23T11:05:07+00:00 monthly 0.2 https://reunionneuro.com/2024/09/04/reunion-neuroscience-joins-the-is-mom-ok-initiative-recognizing-maternal-suicide-prevention-month/ 2024-09-04T11:09:42+00:00 monthly 0.2 https://reunionneuro.com/2024/09/10/reunion-neuroscience-appoints-mark-pollack-m-d-as-chief-medical-officer/ 2024-09-10T11:21:41+00:00 monthly 0.2 https://reunionneuro.com/2024/10/09/reunion-neuroscience-partners-with-seleni-institute-on-effective-diagnosis-and-treatment-of-maternal-mental-health-disorders/ 2024-10-09T12:45:59+00:00 monthly 0.2 https://reunionneuro.com/2024/12/11/reunion-neuroscience-presented-re104-phase-1-data-at-the-2024-american-college-of-neuropsychopharmacology-acnp-63rd-annual-meeting/ 2024-12-11T12:06:47+00:00 monthly 0.2 https://reunionneuro.com/2025/01/06/reunion-neuroscience-announces-program-updates-and-highlights-anticipated-2025-milestones/ 2025-01-06T12:21:27+00:00 monthly 0.2 https://reunionneuro.com/2025/03/04/reunion-neuroscience-announces-participation-in-premiere-maternal-mental-health-event/ 2025-03-04T11:44:47+00:00 monthly 0.2 https://reunionneuro.com/2025/04/06/reunion-neuroscience-presents-rekindle-a-phase-2-clinical-trial-evaluating-re104-for-the-treatment-of-adjustment-disorder-ajd-in-cancer-and-other-medical-illnesses-at-the-anxiety-depression-assoc/ 2025-04-07T01:44:37+00:00 monthly 0.2 https://reunionneuro.com/2025/05/19/reunion-neuroscience-announces-last-patient-dosed-in-reconnect-phase-2-clinical-trial-of-re104-for-the-treatment-of-postpartum-depression-ppd/ 2025-05-19T10:54:01+00:00 monthly 0.2 https://reunionneuro.com/2025/07/22/reunion-neuroscience-announces-publication-of-re104-phase-1-data-in-the-journal-of-clinical-psychopharmacology/ 2025-07-22T12:12:10+00:00 monthly 0.2 https://reunionneuro.com/2025/08/18/reunion-neuroscience-announces-positive-topline-results-from-reconnect-phase-2-clinical-trial-of-re104-for-the-treatment-of-postpartum-depression-ppd/ 2025-08-18T11:07:37+00:00 monthly 0.2 https://reunionneuro.com/2025/09/16/reunion-neuroscience-announces-final-closing-of-its-series-a-financing-and-plans-to-advance-re104-into-clinical-development-for-the-treatment-of-generalized-anxiety-disorder-gad/ 2025-09-16T12:34:26+00:00 monthly 0.2 https://reunionneuro.com/2025/09/30/reunion-neuroscience-announces-first-patient-dosed-in-rekindle-phase-2-clinical-trial-of-re104-for-the-treatment-of-adjustment-disorder-ajd-in-cancer-and-other-medical-illnesses/ 2025-09-30T10:57:29+00:00 monthly 0.2 https://reunionneuro.com/2026/01/12/reunion-neuroscience-announces-program-updates-and-highlights-anticipated-2026-milestones/ 2026-01-12T11:57:26+00:00 monthly 0.2 https://reunionneuro.com/2026/01/20/reunion-neuroscience-presents-full-data-from-reconnect-phase-2-clinical-trial-of-re104-for-the-treatment-of-postpartum-depression-ppd-at-acnp-annual-meeting/ 2026-01-20T12:01:38+00:00 monthly 0.2 https://reunionneuro.com/2026/02/19/reunion-neuroscience-to-participate-in-upcoming-investor-conferences/ 2026-02-19T12:02:41+00:00 monthly 0.2 https://reunionneuro.com/2026/02/23/u-s-fda-grants-reunion-neurosciences-luvesilocin-re104-breakthrough-therapy-designation-status/ 2026-02-23T11:39:49+00:00 monthly 0.2